Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

被引:0
|
作者
Rustgi, V [1 ]
机构
[1] Georgetown Univ, Med Ctr, Liver Transplantat Unit, Washington, DC 20007 USA
关键词
chronic hepatitis C virus; combination treatment; peginterferon alfa-2a; thymalfasin;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The worldwide spread of hepatitis C virus is enormous; chronic hepatitis C virus infection is a leading cause of liver cirrhosis and hepatocellular carcinoma. While treatment options have improved substantially over the last decade, responses are still disappointing, particularly in certain difficult-to-treat groups such as patients who are immunosuppressed or have decompensated disease. Preliminary studies have indicated that combined treatment strategies may provide effective approaches for the future. The combination of thymalfasin with pegylated interferon is currently a promising option for the treatment of patients with chronic hepatitis C virus infection. An ongoing phase 3 study in the USA should provide much needed data to improve the outcome for these patients. (C) 2004 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:S76 / S78
页数:3
相关论文
共 50 条
  • [21] Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Missiha, Sharif
    Heathcote, Jenny
    Arenovich, Tamara
    Khan, Kamran
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (10): : 2181 - 2188
  • [22] Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection
    Masaki, Keiichi
    Suzuki, Fumitaka
    Hara, Tasuku
    Kawamura, Yusuke
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Akuta, Norio
    Kobayashi, Masahiro
    Saitoh, Satoshi
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Kobayashi, Mariko
    Kumada, Hiromitsu
    VIROLOGY JOURNAL, 2015, 12
  • [23] Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Missiha, SB
    Heathcote, EJ
    Arenovich, T
    Khan, K
    GASTROENTEROLOGY, 2005, 128 (04) : A683 - A684
  • [24] Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders
    Hasan, F
    Asker, H
    Al Shamali, M
    Al Kalaoui, M
    Al Nakib, B
    HEPATO-GASTROENTEROLOGY, 2000, 47 (36) : 1642 - 1644
  • [25] Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment:: 24-week interim results of a pilot study
    Poo, JL
    Sánchez-Avila, F
    Kershenobich, D
    García-Samper, X
    Gongora, J
    Uribe, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 : S79 - S81
  • [26] Silibinin as the treatment of chronic hepatitis C with peginterferon/ribavirin non-responders - The search for optimal therapy schemes
    Scherzer, Thomas-Matthias
    Beinhardt, Sandra
    Rutter, Karoline
    Staettermayer, Andreas
    Maieron, Andreas
    Stauber, Rudolf
    Gschwantler, Michael
    Steindl-Munda, Petra
    Hofer, Harald
    Ferenci, Peter
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A25 - A26
  • [27] Peginterferon alfa-2a plus Low Dose Ribavirin versus Peginterferon alfa-2a Monotherapy for Dialysis Patients with Hepatitis C Virus Genotype 1 Infection: A Randomized Trial
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Su, Tung-Hung
    Hung, Peir-Haur
    Tsai, Hung-Bin
    Liu, Chun-Jen
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    HEPATOLOGY, 2012, 56 : 993A - 993A
  • [28] PEGINTERFERON ALFA-2A PLUS RIBAVIRIN COMBINATION TREATMENT IN CHRONIC HEPATITIS C POSTRENAL TRANSPLANT PATIENTS: AN INTERIM ANALYSIS
    Sanai, Faisal M.
    Mousa, Dujanah H.
    Aleid, Hassan
    AlShoail, Ghada
    AlMdani, Abdullah S.
    Al-Ashgar, Hamad I.
    Almeshari, Khalid A.
    Bzeizi, Khalid I.
    HEPATOLOGY, 2010, 52 (04) : 789A - 789A
  • [29] Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment:: 24-week interim results of a pilot study
    Poo, JL
    Sánchez-Avila, F
    Kershenobich, D
    García-Samper, X
    Gongora, J
    Uribe, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (12) : S79 - S81
  • [30] Response-guided Telaprevir Combination Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Peginterferon Alfa-2a/Ribavirin
    Muir, Andrew
    Adiwijaya, Bambang
    Poordad, Fred
    Gritz, Linda
    Bengtsson, Leif
    Luo, Don
    Picchio, Gaston
    Kauffman, Robert
    Adda, Nathalie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S114 - S115